Abstract: A disruptive camouflage pattern system to be used for both military and civilian applications. The system includes specialized techniques for printing the camouflage pattern system unto fabric. The system provides camouflage in both the human visible light and the near infrared range. The system depends on macro pattern resulting from a repeat of a micro pattern. The coloring used includes at least four colorings from dyes that in combination produce a percent reflectance value comparable to that of the negative space of the camouflaged subject's surroundings. The system functions by a macro pattern being disruptive of the subject's shape and a micro pattern having sharp edge units of a size capable of blending the subject into its background. The relative lightness values and percentages of total pattern, wet or dry, are sufficient to produce a percent reflectance of acceptable colors, in terms of lightness values unlike current four-color camouflage.

Abstract: Using the nontoxic PA protein from B. anthracis, a method and composition for use in inducing an immune response which is protective against anthrax in subjects is described.

Abstract: This invention relates to the discovery that toxicity to mustard may be evaluated by diagnostic test means disclosed herein. Upon electrophoretic separation (sodium dodocyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE)) of buffered extract of human skin cells (normal human epidermal keratinocytes (NHEK)) which had been exposed to mustard-type chemical compounds a band at approximately 50,000 to 80,000 daltons molecular weight was found. The protein band constitutes a biomarker.

Abstract: The present invention relates to genetically attenuated superantigen toxin vaccines altered such that superantigen attributes are absent, however the superantigen is effectively recognized and an appropriate immune response is produced. The attenuated superantigen toxins are shown to protect animals against challenge with wild type toxin. Methods of producing and using the altered superantigen toxins are described.

Abstract: The self-erecting structure has resilient lower and upper support loops which provide it with shape and support. Fabric covers the support loops, and is permanently affixed to the support loops. The fabric has a lower, waterproof portion and an upper insect protection portion. The fabric is preferably treated to provide it with insect repellent and insecticide properties. The support loops are made of flexible, resilient rods made of a material, such as a vinylester and fiberglass combination having a diameter selected to enable the support loops to be folded into six loops, whereby the structure can be compactly stored in a rucksack. The method of folding the structure so that it can be stored in such a compact space is also disclosed.

Abstract: Antibodies for binding epitopes of BoNT/A and hybridomas which produce such antibodies are described. The antibodies of the present invention can be used in a method for detecting BoNT/A in a sample and/or in a method for purifying BoNT/A from an impure solution. In addition, the antibodies can be used for passive immunization against BoNT/A intoxication or as intoxication therapy. Another aspect of the invention is a kit for detecting BoNT/A in a sample.

Abstract: A chemical information system having a graphical user interface that allows manipulation of multiple databases having related material and information. The system includes a server and multiple workstations communicating with the server. The databases reside on the server, which may include multiple servers.

Abstract: In this application is described the expression cloning and functional characterization of the CD36-binding domain of Sequestrin. Sequestrin is a surface protein of 215-250 kD size which does not vary in size between parasite strains. The Sequestrin gene appears to be single-copy-number within the genome; noncytoadherent laboratory parasite strains carry the sequestrin gene but fail to express the protein. Sequestrin binds with high affinity to CD36. Sequestrin protein and sequence can be used as a diagnostic, prognostic, and therapeutic tool.

Abstract: Using nucleic acids encoding mutant SEA and SEB exotoxins from Staphylococcus aureus, compositions and methods for use in inducing an immune response which is protective against staphylococcal aureus intoxication in subjects is described.

Abstract: A method is provided for preserving live bacteria by subjecting an aqueous system containing the growing bacteria to drying without special equipment, in the presence of trehalose with or without the addition of divalent cations as stabilizing agents. Further, a dried composition for preservation of aerobic bacteria in a viable state is provided. The dried composition consists essentially of dried viable aerobic bacteria and an appropriate growth medium. The bacteria and growth medium are initially placed in an aqueous solution of 10 mM to 200 mM trehalose and a divalent cation, and dried at room temperature.

Abstract: The invention here relates to recombinant DNA constructs which comprise a Venezuelan equine encephalitis replicon vector and at least one DNA fragment encoding a protective antigen from the Marburg virus. The DNA constructs are useful for inducing an immune response which is protective against infection with Marburg virus in nonhuman primates.

Abstract: A recombinant protein encompassing the complete envelope glycoprotein and a portion of the carboxy-terminus of the membrane/premembrane protein of dengue 2 virus was expressed in baculovirus as a protein particle. The recombinant protein particle was purified and found to provide protection against lethal challenge with dengue 2 virus in mice.

Abstract: A vaccine for promoting an immune response in a mammalian subject includes a eucaryotic plasmid expression vector which include at least part of the envelope gene and optionally, the PreM gene of dengue virus. In order to minimize immune enhancement, vaccines of up to the four serotypes of dengue are combined in a single vaccine. The vaccine in a suitable pharmaceutical carrier constitutes a pharmaceutical composition which is injected into the subject.

Abstract: A controlled release microcapsulate pharmaceutical formulation for burst-free, sustained, programmable release of hydrophocib bioactive agent over a duration from 24 hours to 100 days comprising: and a blend of end-capped uncapped biocompatible, biodegradable poly(lactide/glycolide).

Abstract: Live Brucella vaccines and methods for preparing the live vaccines protective against brucellosis are described. The vaccines are prepared by introducing a deletion in the rfbU gene of a strain of Brucella which results in attenuation of the strain while retaining the desired immunogenicity to initiate a protective immunogenic response. Other strains with varying levels of attenuation are described.

Abstract: An apparatus and method for predicting cognitive performance of an individual based on factors including sleep history and the time of day. The method facilitates the creation of predicted cognitive performance curves that allow an individual to set his/her sleep times to produce higher levels of cognitive performance. The method also facilitates the reconstruction of past cognitive performance levels based on sleep history.

Abstract: Biodegradable pharmaceutical compositions and method for treating bacterial infections therein.

Abstract: This invention pertains in part to a method for delivering functional DNA or antigens. The desired DNA is introduced into attenuated bacteria able to enter cells. Once the bacteria is in the cell, antimicrobial agents are introduced such that they enter the mammalian cell and lyse the bacteria thereby allowing the delivery of carried functional DNA or antigens. The advantages of this method and its uses are described.